Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Peritoneal dialysis (PD) efficacy depends on peritoneal integrity, which can be compromised by fibrotic thickening. This study investigates a novel metabolic-epigenetic pathway in peritoneal fibrogenesis, focusing on histone lactylation-driven chemokine activation.
Chlorhexidine gluconate (CG) or PD solution-induced peritoneal fibrosis mouse model was treated with mesenchymal stem cell-derived extracellular vesicles (MSC-EVs). Single-cell RNA sequencing (scRNA-seq) was performed on peritoneal tissues to analyze cellular interactions. Metabolic reprogramming in injured mesothelial cells was assessed via glycolysis and lactate production assays. Pharmacological inhibition of lactate production was used to validate the role of metabolic regulation. Mechanistic insights into epigenetic modulation were explored through CUT&Tag sequencing using an anti-H3K18la antibody.
MSC-EV treatment significantly ameliorated peritoneal fibrosis and dysfunction. Single-cell analysis revealed attenuated mesothelial-macrophage crosstalk via suppression of CCL2 signaling. Mechanistically, MSC-EVs reprogrammed glycolytic metabolism in mesothelial cells, reducing lactate production and subsequent histone H3K18 lactylation, thereby inhibiting CCL2 transcription. Pharmacologic inhibition of lactate production mirrored these protective effects.
Lactate-induced H3K18 lactylation is a key driver of peritoneal fibrosis. MSC-EVs represent a promising cell-free therapy by targeting metabolic-epigenetic inflammation, offering a potential strategy for preserving peritoneal membrane function in PD.